Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca

 Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca

Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca

Shots:

  • AstraZeneca (AZ) will receive $5M option license fee and additional $20M on approval of Duaklir (aclidinium / formoterol) (product of AZ) from Circassia. Circassia to get US commercialization rights for Tudorza (aclidinium)
  • AZ has also filled sNDA for Tudorza to the US FDA on basis of ASCENT study results, with expected PDUFA date 31 Mar, 2019
  • Tudorza (aclidinium) is a twice daily anticholinergic, indicated for COPD. Duaklir (aclidinium / formoterol) is a FD dry powder of muscarinic antagonist aclidinium bromide & beta agonist formoterol fumarate delivered by breath-actuated multi-dose inhaler Pressair

Click here to read full press release/ article | Ref: Circassia Image: Philly

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post